With $37M Investment and New Corporate Partner, San Diego’s Cibus to Develop Enhanced Crop Strains for Europe
News Oct 12, 2009
Under the joint development partnership, Cibus will use its proprietary technology (which offers an alternative approach to inserting foreign genes to create genetically modified crops) to develop new plant traits in five unidentified crops for the European market. As part of the related agreement, Makhteshim-Agan, or MAI, will make its investments based on Cibus’s progress—and gradually acquire a 50.1 percent stake.
Cibus describes its technology, known as Rapid Trait Development System, or RTDS, as a “smart-breeding technology” that introduces desirable genetic traits in a plant by using directed mutagenesis, a process that takes advantage of mechanisms of gene repair. The company says that every time a cell copies its DNA, it makes “scrivener” errors, akin to typographical errors in the genetic code. Such variations are common, and according to Cibus, are part of natural variation. Cibus says its technology uses the DNA repair machinery that corrects such typos, and directs it instead to make changes in a specific way that produces the desired trait in the targeted gene.
Cibus hopes its approach will be acceptable to environmental groups and activists opposed to genetically modified organisms, or GMOs. The European market, in particular, has resisted introduction of genetically modified crops.
Giant Viruses Invent Their Own GenesNews
Three new members have been isolated and added to the Pandoravirus family. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised scientists when they were discovered a few years ago. This new study notes that pandoraviruses appear to be factories for new genes – and therefore new functions.
Therapeutic CRISPR Could Be Cancer RiskNews
Therapeutic use of gene editing with the so-called CRISPR-Cas9 technique may inadvertently increase the risk of cancer, according to a new study. Researchers say that more studies are required in order to guarantee the safety of these ‘molecular scissors’ for gene-editing therapies.